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Background: A safe, effective vaccine for breastfeeding infants born to HIV-1-positive mothers could
complement antiretroviral therapy (ART) for prevention of mother-to-child transmission of HIV-1. To
date, only a few HIV-1 vaccine candidates have been tested in infants.
Trial design: A phase I/II randomized controlled trial PedVacc 002 was conducted to determine the safety
and immunogenicity of a single, low dose of MVA.HIVA vaccine delivered intramuscularly to healthy
20-week-old infants born to HIV-1-positive mothers in Nairobi, Kenya.
Methods: Pregnant HIV-1-positive women in the 2nd/3rd trimester of gestation were enrolled, provided
with ART and self-selected their infant-feeding modality. Infants received nevirapine and cotrimoxazole
prophylaxis. At 20 weeks of age, eligible HIV-1-negative infants were randomized to vaccine versus no-
treatment arms and followed to 48 weeks of age for assessments of vaccine safety, HIV-1-speciﬁc T-cell
responses and antibodies to routine childhood vaccines.
Results: Between February and November 2010, 182 mothers were screened, 104 were eligible and fol-
lowed on ART during pregnancy/postpartum, of whom 73 had eligible infants at 20 weeks postpartum.
Thirty-six infants were randomized to vaccine and 37 to no treatment. Eighty-four percent of infants
breastfed, and retentionat48weekswas99%.Adverseeventswere rareandsimilarbetween the twoarms.
HIV-1-speciﬁc T-cell frequencies in interferon- ELISPOT assay were transiently higher in the MVA.HIVA
arm (p=0.002), but not above the threshold for a positive assay. Protective antibody levels were ade-
quate and similar between arms for all routine childhood vaccines except HBV, where 71% of MVA.HIVA
subjects compared to 92% of control subjects were protected (p=0.05).
Abbreviations: rMVA, recombinant modiﬁed vaccinia virus Ankara; HIV-1, human immunodeﬁciency virus type 1; HEU, HIV-1-exposed uninfected; ART, antiretroviral
herapy; PMTCT, prevention of mother-to-child transmission of HIV-1; ZDV, zidovudine; TDF, tenofovir; 3TC, lamivudine; LPV/RTV, lopinavir/ritonavir; EFV, efavirenz; NVP,
evirapine; HBV, hepatitis B virus; OPV, oral polio vaccine; KEPI, Kenyan Expanded Program on Immunization; Dtx, diphtheria toxin; Ttx, tetanus toxin (Ttx); Hib,Hemophilus
nﬂuenzae type b; KNH, Kenyatta National Hospital; IQR, interquartile range; WAZ, weight-for-age Z-score.
∗ Corresponding author at: The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. Tel.: +44 0 1865 617630;
ax: +44 0 1865 617608.
E-mail address: tomas.hanke@ndm.ox.ac.uk (T. Hanke).
1 Present address: Institut Pasteur du Laos, Samsenthai Rd, Ban Kao-gnot, PO Box 3560, Vientiane, Lao Democratic People’s Republic.
ttp://dx.doi.org/10.1016/j.vaccine.2014.08.034
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Conclusions: This trial tested for the ﬁrst time anMVA-vectored candidateHIV-1 vaccine inHIV-1-exposed
infants inAfrica, demonstrating trial feasibility andvaccine safety, low immunogenicity, and compatibility
with routine childhood vaccinations. These results are reassuring for use of theMVAvector inmore potent
prime-boost regimens.
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the breastfeeding period while formula-fed infants stopped at 10© 2014 The Authors. P
. Introduction
In 2012, an estimated 260,000 children became infected
ith the human immunodeﬁciency virus type 1 (HIV-1)
www.unaids.org), the majority of whom acquired the virus
rom their mothers. The UNAIDS’s ambitious Global Plan towards
he Elimination of New HIV-1 Infections among Children by 2015 and
eeping Their Mothers Alive aims to decrease the number of new
ediatric infections by 90% (www.unaids.org). Although the Global
lan is well underway, only an estimated 57% of HIV-1-positive
regnant women in low- and middle-income countries accessed
ppropriate prevention of mother-to-child HIV-1 transmission
PMTCT) antiretroviral regimens in 2012. Incomplete access to
ntiretroviral therapy (ART), ART side effects [1–8], non-adherence
nd/or HIV-1 drug resistance can lead to persistent risk of mother-
o-childHIV-1 transmission despite expansion of PMTCTprograms.
hus, effective HIV-1 vaccines to protect infants against breast
ilk HIV-1 transmission may complement and enhance current
MTCT strategies.
Vaccine prevention of breast milk HIV-1 transmission will
equire the priming vaccine to be administered within the ﬁrst few
ays after birth, followed by boost(s) soon after. To date, there have
eenover 650 clinical studies assessing candidateHIV-1 vaccines in
umans. However, fewer than 10 of these studies tested HIV-1 vac-
ine safety and immunogenicity in infants (www.clinicaltrials.gov),
espitemajor differences in natural HIV-1 infection [9] and respon-
iveness to vaccinations [10,11] between adults and infants/young
hildren. Infants have distinct characteristics that may inﬂuence
heir response toHIV-1 vaccines. Despite evidence of infants’ lower
apacity for some immune responses, they have some potential
dvantages for generating responses. For example, infants have
ewer competing memory T-cell clones that exist at the time of
accination, making ‘space’ to establish new long-term cellular
emory [12]. Thus, testing of candidate vaccines in pediatric popu-
ations is important for appropriate development of vaccines early
n the pipeline [13].
One of the leading boosting vectors for genetic subunit vaccines
s modiﬁed vaccinia virus Ankara (MVA), known for its excellent
afety and immunogenicity record fromhuman trials involving sev-
ral thousands of individuals [14]. As an inroad for MVA-vectored
IV-1 vaccine use in infants, we tested a low dose of vaccine
VA.HIVA [15] in parallel in infants born to HIV-1-negative moth-
rs (PedVacc 001 trial in The Gambia) and in infants born to
IV-1-positive mothers (PedVacc 002 trial in Kenya). MVA.HIVA
elivered the ﬁrst ever immunogen derived from an African clade
HIV-1 [16] to reach human evaluation in Africa.
When the PedVacc 001 and 002 trials were conceived in
007, only three studies of active immunization in infants were
ublished. These other studies evaluated 3 Env-derived subunit
roteins and 3 canarypoxvirus (ALVAC)-vectored vaccines in Pedi-
tric AIDS Clinical Trials Group protocols (PACTG) 320 [17–19] and
26 [20,21] and HIV Pediatric Trials Network (HPTN) protocol 027
22]. The tested ALVAC and protein vaccines caused no increase
n serious adverse events (SAE) and elicited promising immune
esponses similar to those observed in adults.We recently reported
hat the PedVacc 001 trial had excellent safety and marginal
mmunogenicity among20-week-oldGambian infants born toHIV-
-negative mothers [23]. Here, we report on the administration ofhed by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
MVA.HIVA to infants born toHIV-1-positivemothers inKenya (Ped-
Vacc 002) with the primary aim to assess its safety. This was the
ﬁrst time that a rMVAvaccinewith anHIV-1-derived transgenewas
administered to infants born to HIV-1-positive mothers.
2. Materials and methods
2.1. Study design
The Pediatric Vaccine (PedVacc) 002 study was a single-site,
phase I/II, open, randomized, controlled trial of candidate HIV-1
vaccine MVA.HIVA compared to no treatment. The primary out-
come was MVA.HIVA vaccine safety.
2.2. Ethics and regulatory approvals
Approvals to conduct the study were granted by the
Pharmacy and Poisons Board, Ministry of Medical Services,
Kenya (ref. PPB/ECCT/08/25-2/10), Kenyatta National Hospital
(KNH)/University of Nairobi Research Ethics Committee (ref.
P266/10/2008), Nairobi University Institutional Biosafety Commit-
tee (ref. UON/CHS/PRINC/ADM1/SC6/IBC.CTTE/13), Oxford Tropical
Research Ethics Committee (ref. OXTREC 52-08), University of
Washington Institutional review Board (ref. HSD 35079), and the
Stockholm Regional Ethics Committee (ref. 2009/1591-31/1). The
study was conducted according to the principles of the Declaration
of Helsinki (2008) and complied with the International Conference
on Harmonization Good Clinical Practice guidelines.
2.3. Study population
The study was conducted at KNH in Nairobi, Kenya. HIV-1-
positive pregnantwomen in their 2nd/3rd trimesterwere recruited
from antenatal clinics at KNH and Nairobi City Council clinics.
Women were eligible to participate if they were aged 18 years or
above, had CD4+ cell count greater than 350l−1, WHO stage 1 or
2 disease, planned to deliver at KNH, and planned to remain in the
Nairobi area for one year after delivery. Women in the study gave
written informed consent and the infant’s father, or other fam-
ily member or signiﬁcant person co-signed the consent form for
participation. Mothers were provided with ART for PMTCT as per
WHO Option B guidelines consisting of zidovudine (ZDV) or teno-
fovir (TDF), lamivudine (3TC), and lopinavir/ritonavir (LPV/RTV)
or efavirenz (EFV) or nevirapine (NVP) during pregnancy, delivery
and throughout breastfeeding. Women were counseled on feeding
options and provided formula milk if they elected to use replace-
ment feeding.
Within 3 days of birth, singleton infants were enrolled if they
weighed at least 2.5 kg and did not have congenital defects or
underlying disease that might compromise evaluation of response
to the candidate vaccine. Infants received NVP prophylaxis for the
ﬁrst 6 weeks of life and cotrimoxazole prophylaxis from 6 weeks
of age. Breastfeeding infants continued cotrimoxazole throughoutweeks if their 6-week HIV-1 test was negative. Infants received
Kenyan Expanded Program on Immunization (KEPI) vaccinations,
which included BCG and oral poliovirus vaccine (OPV) at birth, OPV
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ndPentavalent vaccine (diphtheria toxin [Dtx], tetanus toxin [Ttx],
hole cell pertussis [Ptx], Hemophilus inﬂuenzae type b [Hib] and
epatitis B virus [HBV] surface antigen [HBsAg]) at 6, 10 and 14
eeks of age. Pneumoccocal conjugate vaccine 10, introduced in
he course of the study was administered to infants at variable
ges. During study visits, a standard questionnaire on infant health
nd immunization was completed. At 20 weeks, infants were ran-
omized if they had received all scheduled KEPI vaccines, were
IV-1-uninfected, had weight-for-age Z-scores no more than 2
tandard deviations below normal, had no acute or chronic dis-
ase, had no history of anaphylaxis reaction to prior vaccination,
nd baseline laboratory investigations were within normal ranges.
.4. The study vaccine and its administration
MVA.HIVA is a recombinant non-replicating poxvirus, which
arries theHIVA transgene inserted into the thymidine kinase locus
f the parental MVA genome under the early/late P7.5 promoter
16]. MVA.HIVA was manufactured under current Good Manufac-
uring Practice conditions by IDT, Germany. It was provided in vials
f 200l at 5×108 plaque-forming units (PFU)ml−1 in 10mM
Fig. 1. Trial proﬁle. Diagram indicating the numbers of infa32 (2014) 5801–5808 5803
Tris–HCl buffer pH 7.7 and 0.9% NaCl, and stored at ≤−20 ◦C. On
the day of administration, each vial was thawed at room tem-
perature and given within 1h of thawing. Infants randomized to
vaccine group received a single intramuscular dose of 5×107 pfu
of MVA.HIVA, while the control group received no treatment. Vac-
cinated infants were observed in the clinic for 1h post-vaccination
andvisited at homeafter 24 and48h to assess for adverse reactions.
2.5. Participant follow-up and safety monitoring
Randomization was generated at Karolinska Institute using
a blocked design and participants were assigned using sealed
envelopes. After randomization, medical history and examinations
were conducted at 21, 28, 36 and 48 weeks of age. At 21 and 28
weeks, hematology and biochemistry tests were done as described
below. Local, systemic and laboratory AEs, and relationship to
MVA.HIVA were graded as per Clinical Protocol (Supplementary
Information). Palpable lymph nodes, redness and induration were
scored according to their diameters. Any Grade 3 or 4 laboratory AE
was conﬁrmed by re-test. An internal trial safety monitor reviewed
Grade 3 and 4 events in real time and these were reported to the
nts screened and followed up throughout the study.
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fracture, while among controls, 2 infants had neutropenia and 1
had pneumonia (Table 4). None of these events were considered
vaccine-related.
Table 1
Characteristics of study participants.
Control group (n=37) Vaccine group (n=36)
Maternal
characteristics at
enrollment during
pregnancy
Maternal age (years) 27 (23,31) 27 (22, 30.5)
Maternal CD4+ cell
count (l−1)
526 (428,663) 549 (443, 658.5)
Gestational age
(weeks)
28 (20,30) 30 (27,32)
Previously used ART 25 (67.6%) 23 (63.8%)
On AZT-based ART 16 (43.2%) 17 (47.2%)
Infant characteristics at
1 week before
randomization (20
weeks postpartum)
Male sex 16 (43.2%) 16 (44.4%)
Birth weight (g) 3,150 (3,000,3,400) 3,125 (2,900,3,405)
WAZa −0.66 (−1.22, 0.52) −0.22 (−0.92, 0.71)
MUACb (cm) 14 (14,15) 14.5 (14, 15)
Hemoglobin (gdl−1) 11.4 (10.9, 12.3) 11.85 (11.05, 12.3)
White Blood Cell
count×103 (l−1)
8.5 (7.6, 10.1) 9.85 (7.70,11.35)
Platelet count×103
(l−1)
423 (308,531) 428 (377.0, 514.5)
Neutrophil
count×103 (l−1)
1.35 (1.09, 1.59) 1.45 (1.12, 2.31)
Creatinine (M) 37(31,43) 36.5 (31.5, 41)
Alanine 16 (12,23) 19.5 (14.0, 25)804 I.N. Njuguna et al. / Va
NH Research Ethics committee. Study procedures were reviewed
egularly by an external monitor. An external Data Monitoring and
thics Committee reviewed safety data at 6-monthly intervals.
.6. Blood sampling schedule and handling
Laboratory personnel were blind to group allocation. Five ml of
lood (4mlEDTA, 1ml clotted)was collected at 19, 21, 28, 36 and48
eeks of age. MVA.HIVA immunogenicity was tested at all 5 time
oints; hematology, biochemistry (including alanine transaminase
ALT] and creatinine tests), and CD4+ cell counts were conducted at
9, 21 and 28 weeks. KEPI vaccine antibody responses were deter-
ined at 19 and 21 weeks. HIV-1 testing was performed using
IV-1 DNA PCR at birth, 6, 10, 14 and 20 weeks; HIV-1 viral load
t 19, 28, 36 and 48 weeks and HIV-ELISA at 48 weeks. Periph-
ral blood mononuclear cells (PBMC) were isolated and used for
nterferon (IFN)- ELISPOT assays or frozen [23].
.7. IFN- ELISPOT assay
Fresh ex vivo and cultured IFN- ELISPOT assays were carried
ut as previously described [23]. An assay failed quality control if
hemean backgroundwas >20 spot-forming units (SFU)/well (>100
FU/106 PBMC) or mean phytohemagglutinine response was <30
FU/well (<150 SFU/106 PBMC). A response was considered posi-
ive if the mean stimulated response was at least twice the mean
ackground response and the net response (with background sub-
racted) was ≥50 SFU/106 PBMC.
.8. KEPI vaccine antibody responses
Microsphere-based multiplex assays were performed at the
ational Institute forPublicHealthand theEnvironment, Bilthoven,
he Netherlands to quantify serum IgG antibodies against Ptx, Dtx,
tx and Hib as described previously [24]. Anti-HBsAg antibody lev-
ls were measured using an anti-HBsAg enzyme immunoassay kit
ETI-AB-AUK-3, Diasorin, Italy). Type 1 poliovirus IgG levels were
etermined by a neutralization assay as described previously [25].
nfants with inadequate vaccine responses were offered revaccina-
ion.
.9. Statistical analysis
Non-parametric testswere used to compare immune responses,
ematology and biochemistry parameters. We reported local and
ystemic AEs occurring 8 weeks after vaccination. Infants could
ontribute to several AEs, and those with more than one report
f the same event were assigned to the highest grade recorded for
hat condition if it was ongoing. If an event occurred in 2 or more
istinct episodes, these were considered separate events. Two-
ailed Mann–Whitney tests were used to compare the two trial
andomization arms, and Wilcoxon matched-pairs tests assessed
he changes in an infant’s responses over time. The alpha level
as set at <0.05 for statistical signiﬁcance. Poisson models were
sed to examine replicate wells of the ELISPOT assays and extreme
utliers that were identiﬁed (using a Bonferroni correction for
ultiple testing) were excluded prior to averaging. Data analysis
as conducted with Stata version 12 (StataCorp, College Station,
exas).
. Results.1. Trial participants
Between February and November 2010, 182 mothers were
creened, of whom 104 were eligible for the study. Of the 10232 (2014) 5801–5808
deliveries, 94 infantswere eligible for the study, including 79breast
feeders and 15 formula feeders (Fig. 1). At 20 weeks of age, 73
infants were randomized to receive the MVA.HIVA vaccine (n=36)
or no treatment (n=37). Mothers of randomized infants had a
median age of 27 years (IQR 22-31) and were enrolled at a median
gestational age of 29 weeks (IQR 24, 32). The median infant birth
weight was 3.1 kg (IQR 2.95, 3.4). Seventy-one infants completed
visit 10 (48 weeks) within the scheduled visit window, with one
infant attending late, giving an overall retention of 99% at 48weeks.
Therewere no signiﬁcant differences between the 2 groups at base-
line (Table 1).
3.2. MVA.HIVA was well tolerated
Most vaccinated infants had pain, redness and hardness on day
1 and 2 post-vaccination (Table 2). One week post-vaccination, 1
infant hadgrade1pain, 2 had rednessmeasuring0.3 and0.5 cmand
14 had hardness with median (range) diameter of 0.5 (0.1–1) cm.
All these events had resolved by 8 weeks post-vaccination. Three
infants had lymphadenopathy measuring 0.5 cm in 2 infants and
0.6 cm in 1 infant at week 1; these resolved by week 8. Another
infant had lymphadenopathymeasuring 0.5 cm atweek 8 (Table 2).
As previously reported, 58% infants displayed hematologic toxi-
cities pre-randomization [5]. However, there were no signiﬁcant
hematologyor biochemistrydifferences between thevaccinees and
controls post-vaccination (Table 3). There were 8 severe adverse
events, 5 in the vaccine arm and 3 in the control arm. Among
vaccinees, 1 infant had an upper respiratory tract infection, 2
had gastroenteritis, 1 had septicemia and 1 had a depressed skulltransaminase (U l−1)
Values are given as median with interquartile range (IQR) in parentheses or n (%).
a Weight-for-age Z-score.
b Mid-upper arm circumference.
I.N. Njuguna et al. / Vaccine 32 (2014) 5801–5808 5805
Table 2
Local reactogenicity during the ﬁrst 8 weeks after vaccination.
n=36 Day of vaccination Day 1 Day 2 Week 1 Week 8
Pain 1 28 20 1 0
Grade 1 1 28 19 1 0
Grade 2 0 0 1 0 0
Grade 3 0 0 0 0 0
Redness 0 31 26 2a 0
Median (range) (cm) 0.2 (0.1–1) 0.3 (0.1–1.2)
Hardness 0 17 20 14 0
Median (range) (cm) 0.4 (0.1–0.8) 0.4 (0.1–1) 0.5 (0.1–1)
Ulceration 0 0 0 0 0
Lymph nodeb 0 1 0 3 1
a Two infants had redness at week 1 measuring 0.5 and 0.3 cm.
b One infant had lymphadenopathy noted at day 1 and week 1 at 0.6 cm. Two other infants had lymphadenopathy at week 1 measuring 0.5 cm. Another infant had
lymphadenopathy measuring 0.5 cm at week 8. All events resolved spontaneously.
Table 3
Hematology and biochemistry data.
Week 19 Week 21 Week 28
Vaccine Control Vaccine Control Vaccine Control
Hemoglobin (gdl−1) 11.4 (10.4, 12.1) 11.2 (10.4, 12.3) 11.3 (10.8, 11.8) 11.1 (10.6, 12.4) 11.0 (10.3,11.7) 11.1 (10.7, 11.9)
White cell count×103
(l−1)
9.5 (6.1, 11.0) 8.5 (6.3, 10.1) 10.4a (7.5, 12.3) 8.7 (7.0, 11.3) 10.3b (8.1, 12.6) 9.5 (7.8, 11.6)
Platelet count ×103
(l−1)
412 (290.5, 517.8) 319 (203.5, 524.5) 426 (289, 578.3) 471 (246, 576.5) 407 (290,538) 464 (357, 556.5)
Neutrophil count×103
(l−1)
1.3 (1.0, 2.2) 1.3 (1.0, 1.6) 1.7 (1.0, 2.3) 1.4 (1.0, 1.9) 1.5 (1.2, 2.4) 1.8c (1.6, 2.9)
Creatinine (M) 36.5 (31.3, 41.5) 37 (31, 43.5) 38.5 (33.2, 43) 39 (35,42) 36 (33,41) 37.5 (31.3, 42.5)
Alanine transaminase
(U l−1)
19.5 (14, 25) 16 (11.5, 23.5) 18 (13.3, 26.5) 19 (14,29) 18 (15,23) 18.5 (14, 23)
Values are given as median (IQR).
a p=0.08.
b p=0.06.
c p=0.08.
Table 4
Adverse events during the ﬁrst 8 weeks after vaccination.
Vaccine group (83 events) Control group (72 events)
Grade Grade
Total 1 2 3 4 Total 1 2 3 4
Systemic
Upper respiratory tract infection 22 20 1 1 0 16 16 0 0 0
Gastroenteritis 8 6 0 2 0 6 6 0 0 0
Conjunctivitis 3 3 0 0 0 2 2 0 0 0
Cough 4 4 0 0 0 0 0 0 0 0
Fungal skin rash 2 2 0 0 0 1 1 0 0 0
Fever 2 2 0 0 0 1 1 0 0 0
Pneumonia 1 0 1 0 0 1 0 0 1 0
Rash 3 3 0 0 0 0 0 0 0 0
Otitis media 0 0 0 0 0 1 1 0 0 0
Septicemia 1 0 0 1 0 0 0 0 0 0
Eczema 0 0 0 0 0 1 1 0 0 0
Abscess 0 0 0 0 0 1 0 1 0 0
Colic 0 0 0 0 0 1 1 0 0 0
Depressed skull fracture 1 0 0 1 0 0 0 0 0 0
Constipation 0 0 0 0 0 1 1 0 0 0
Laboratory
0
0
0
3
T
7
t
1Elevated creatinine 17 15 2
Neutropenia 12 6 6
Anemia 7 6 1
.3. Vaccination did not induce signiﬁcant, detectable anti-HIV-1
-cell responsesA total of 262 ex vivo IFN- ELISPOT assays were conducted for
2 infants, with 18, 28, 14 and 12 infants tested at 5, 4, 3 and fewer
ime points, respectively. Results were also obtained for a total of
42 cultured assays from51 infantswith 39 and 12 infants tested at0 16 13 3 0 0
0 12 6 4 1 1
0 12 7 5 0 0
3 and2 timepoints, respectively. Overall, nopositiveHIV-1-speciﬁc
T-cell responses were detected using either of the IFN- ELISPOT
assays, although transiently higher frequencies were detected in
the MVA.HIVA arm (p=0.002) in fresh ex vivo assays, but not above
the threshold frequencies considered as a positive result (Supple-
mentary Table S1). Note, that infants have up to 15-fold higher
PBMC counts per 1ml of peripheral blood compared to adults.
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Table 5
Antibody titres elicited by childhood vaccines one week post-vaccination.
EPI vaccine Protective antibody
level
Control week 21
median (min, max)
n/total (%)
Vaccine week 21
median (min, max)
n/total (%)
p—Difference between
vaccine and control
arm
Poliovirus ≥1:8 1024 (64,1024) 1024 (128,1024) 0.26
HBsAg (mIUml−1) ≥10 55.0 (10, 1000) 27.0 (10, 1000) 0.32
HBV protective levels 24/26 (92%) 17/24 (71%) 0.05
Dtx (IUml−1) ≥0.01 0.8 (0.08, 5.3) 0.8 (0.03, 3.5) 0.25
Ttx (IUml−1) ≥0.01 3.2 (0.76, 9.0) 2.7 (0.16, 9.2) 0.35
−1 4 (0.13
92%)
1, 437
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Hib protective levels 25/26 (
Ptx (IUml−1) Unknown 39(
.4. Except for HBV, MVA.HIVA administration did not affect KEPI
nduction of protective antibodies
KEPI vaccinations elicited protective antibody levels to Hib,
oliovirus, diphtheria, tetanus and pertussis in a majority of the
nfants with no statistically signiﬁcant differences between the
wo arms (Table 5). For HBV, immune response to vaccine differed
etween the two groups; 71% of MVA.HIVA arm subjects versus
2% of control subjects achieved protective antibody levels to HBV
≥10mIUml−1) 1 week post-vaccination (p=0.05), reﬂecting the
reater drop in levels in the MVA.HIVA arm between weeks 19 and
1 (p=0.025).
.5. MVA.HIVA recipients remained HIV-1 test negative
Infants’ blood was regularly tested for HIV-1-speciﬁc DNA or
ntibodies. Post-randomization, all infants remained HIV negative
t repeated serial testing.
. Discussion
MVA is a boosting vector for recombinant subunit vaccines
nder development for prevention of a number of infectious dis-
ases [14] for use in adults and infants [23,26,27]. The PedVacc 002
rial reported here demonstrated safety of MVA-vectored vaccines
xpressing an HIV-1-derived immunogen in 20-week-old HIV-1-
egative African infants born to HIV-1-positive mothers.
Administration of one low MVA.HIVA vaccine dose without a
eterologous prime or boost was not sufﬁciently immunogenic to
nduce HIV-1-speciﬁc, IFN--producing T cells in the circulating
loodof20-week-old infants. Therewasalsono indicationof induc-
ion or boosting of infants’ HIV-1-speciﬁc T-cell responses through
xposure to their mother’s virus. This is neither unexpected nor
iscouraging for future use of this vaccine modality. First, because
f the young age of vaccine recipients, we used a low intramuscu-
ar dose of MVA.HIVA, which was 4-fold lower than the adult dose
f 2×108 pfu [15] likely to be used in future studies. In addition,
e and others have shown that vaccines vectored by MVA are poor
rimers of transgene-speciﬁc T-cell responses, but when given to
ell-primed individuals such as HIV-1-positive patients on ART or
olunteers whose responses have already been expanded by DNA-
nd/or simian adenovirus-vectored vaccines, rMVA delivered up to
10-fold boost to the existing frequencies of transgene-speciﬁc T-
ells [15,28]. In our parallel PedVacc trials 001 and002, this prudent
MVA vaccine dose was administered as the ﬁrst stage of develop-
ng a recombinant BCG-MVA regimen with a possible extension
o a dual HIV-TB vaccine platform [29–35]. Since the conception
f these trials in 2007, both the immunogen design and its pre-
entation to the immune system have evolved. Recently, a prime
ith non-replicating recombinant simian adenovirus followed by
n rMVAboostwas shown to induce high frequencies of transgene-
peciﬁc T cells in UK adults [36–38]. The immunogen HIVA has, 190.3) 3.0 (0.08, 50.2) 0.29
25/27 (93%) 0.51
) 48 (1, 654) 0.96
been replaced by a pan-clade immunogen based on the most con-
served regions of the HIV-1 proteome [36,39], which addresses
virus diversity and escape more efﬁciently [28]. Furthermore, for
a ﬁnal vaccine regimen, an efﬁcient T-cell vaccine will likely be
combined with vaccines inducing broadly neutralizing antibodies
when these become available [40].
MVA.HIVA did not interfere with responses to polio, diphtheria,
pertussis, tetanus or Hib vaccines. However, a higher proportion
of vaccinated infants failed to develop protective levels of antibod-
ies to HBV. This difference was not observed in the PedVacc 001
study, where MVA.HIVA was administered to HIV-1-negative chil-
dren of HIV-1-negative Gambian mothers and similar responses
to the six childhood vaccines were found in vaccinees and con-
trols [23]. A very good safety record of MVA.HIVA also concurs
with candidate TB vaccine MVA85A, which was well tolerated in
clinical trials in infants [26,27,41,42]. In the PACTG 326 and HPTN
027 studies, where non-replicating canarypoxviruses were admin-
istered to HIV-1-exposed uninfected (HEU) infants at birth, no
differences in vaccine responses were found between infants and
adults [20–22]. Nevertheless, immune system deﬁcits that impair
immune responses to childhood vaccines were described among
HEU infants, not only resulting from abnormalities in the immune
system [43–46], but also from antiretroviral prophylaxis admin-
istered to mothers for PMTCT [45]. Humoral vaccine responses
among HEU infants were variable with similar responses being
described 2 weeks after last vaccination [47] and lower HBV and
tetanus titers 4weeks after last vaccination [48]when compared to
HIV-1-unexposed infants. In addition, HBV antibody level declined
by up to 50% over time among HEU infants 6 months after the third
vaccination dose emphasizing the need for boost vaccinations in
this group [49]. Thus, reduced responses to HBV vaccine among
HEU recipients of MVA.HIVA require further evaluation.
There was a high level of retention in this study despite the
intensive study visits, demonstrating the feasibility of conducting
vaccine studies among infants in the region. This ﬁnding is simi-
lar to other infant HIV-1 vaccine trials conducted in Africa [20–23]
and provides reassurance for future vaccine evaluations in this age
group.
In conclusion, MVA.HIVA was safe but not sufﬁciently immuno-
genic as a stand-alone vaccine in African infants. The safety proﬁle
demonstrated in PedVacc 001 [23] and 002 trials in infants, and
immunogenicity of MVA-vectored vaccines observed in heterolo-
gous prime-boost regimens [29–35] support the use of MVA as a
vaccine vector in infants. In addition to evaluating vaccine perfor-
mance, both trials built capacity byusing local ethics and regulatory
review processes and establishing/expanding local infant HIV-1
vaccine trial expertise and facilities for evaluationsof futurevaccine
candidates.Acknowledgements
The authors thank themembers of theDMEC Frances Gotch (Co-
Chair), Glenda Gray (Co-Chair), Maria Grazia Valsecchi, Laura Guay,
ccine
A
W
t
P
R
a
C
f
C
A
p
N
c
p
1
a
2
2
A
f
j
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[I.N. Njuguna et al. / Va
ggrey Wasunna and Eduard Sanders for their guidance and input.
e also acknowledge the PedVacc 002 study team and the assis-
ance of the staff in the MRC clinical laboratories. The HIV-1 PTE
eptides were obtained through the AIDS Research and Reference
eagent Program, Division of AIDS, NIAID, NIH. Finally, we thank
ll study participants and their parents.
Theworkwas supported by European andDeveloping Countries
linical Trials Partnership (EDCTP; CT.2006.33111.002) with co-
unding from Bill and Melinda Gates Foundation, Medical Research
ouncil UK and Swedish International Development Cooperation
gency (SIDA). Research reported in this publication was also sup-
orted in part by NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA of the
ational Institutes of Health under award number P30A1027757.
Clinical Trials.gov Registry (NCT00981695) http://www.
linicaltrials.gov/ct2/show/NCT00981695?term=MVA.HIVA+and+
edvacc&rank=1
The Pan African Clinical Trials Registry (PACTR20090-
0001152787) http://www.pactr.org/ATMWeb/appmanager/atm/
tmregistry? nfpb=true& windowLabel=basicSearch 1
&basicSearch 1 2 actionOverride=%2Fpageﬂows%2Ftrial%
FbasicSearch%2FviewTrail&basicSearch 1 2id=115.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.vaccine.2014.08.034.
eferences
[1] Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, et al.
Hematologic and hepatic toxicities associated with antenatal and postnatal
exposure to maternal highly active antiretroviral therapy among infants. AIDS
2008;22:1633–40.
[2] Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal-
fetal transfer and amniotic ﬂuid accumulation of nucleoside analogue reverse
transcriptase inhibitors in human immunodeﬁciency virus-infected pregnant
women. Antimicrob Agents Chemother 2004;48:4332–6.
[3] ChappuyH, Treluyer JM, Rey E,Dimet J, FoucheM, FirtionG, et al.Maternal-fetal
transfer and amniotic ﬂuid accumulation of protease inhibitors in pregnant
women who are infected with human immunodeﬁciency virus. Am J Obstet
Gynecol 2004;191:558–62.
[4] Feiterna-Sperling C, Weizsaecker K, Buhrer C, Casteleyn S, Loui A, Schmitz T,
et al. Hematologic effects of maternal antiretroviral therapy and transmission
prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune
Deﬁc Syndr 2007;45:43–51.
[5] Njuguna I, Reilly M, Jaoko W, Gichuhi C, Ambler G, Maleche-Obimbo E,
et al. Infant neutrapenia associated with breastfeeding during maternal
antiretroviral treatment for prevention ofmother-to-child transmission ofHIV.
Retrovirology 2014;6:1–5.
[6] Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al. Effect of
perinatal antiretroviral drugexposureonhematologic values inHIV-uninfected
children: An analysis of the women and infants transmission study. J Infect Dis
2006;194:1089–97.
[7] Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, et al.
Antiretroviral concentrations in breast-feeding infants of women in Botswana
receiving antiretroviral treatment. J Infect Dis 2005;192:720–7.
[8] Six Week Extended-Dose Nevirapine Study, Bedri TA, Gudetta B, Isehak
A, Kumbi S, Lulseged S, et al. Extended-dose nevirapine to 6 weeks of
age for infants to prevent HIV transmission via breastfeeding in Ethiopia,
India, and Uganda: an analysis of three randomised controlled trials. Lancet
2008;372:300–13.
[9] Richardson BA,Mbori-NgachaD, Lavreys L, John-Stewart GC, Nduati R, Pantele-
eff DD, et al. Comparison of human immunodeﬁciency virus type 1 viral loads
in Kenyan women, men, and infants during primary and early infection. J Virol
2003;77:7120–3.
10] Mo H, Monard S, Pollack H, Ip J, Rochford G, Wu L, et al. Expression patterns
of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes
from cord and adult blood. AIDS Res Hum Retroviruses 1998;14:607–17.
11] Luzuriaga K, Sullivan JL. Pediatric HIV-1 infection: advances and remaining
challenges. AIDS Rev 2002;4:21–6.
12] Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, com-
partmentalization and homeostasis. Nat Rev Immunol 2014;14:24–35.
13] Cunningham CK, McFarland E. Vaccines for prevention of mother-to-child
transmission of HIV. Curr Opin HIV AIDS 2008;3:151–4.
14] Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Clinical applications of
attenuated MVA poxvirus strain. Expert Rev Vaccines 2013;12:1395–416.
[32 (2014) 5801–5808 5807
15] Hanke T, GoonetillekeN,McMichael AJ, Dorrell L. Clinical experiencewith plas-
mid DNA- and modiﬁed vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade
A vaccine inducing T cells. J Gen Virol 2007;88:1–12.
16] Hanke T, McMichael AJ. Design and construction of an experimental HIV-1
vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;6:951–5.
17] Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, et al.
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in
neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230
Collaborators. J Infect Dis 2000;181:890–6.
18] Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, et al.
Safety of 2 recombinant human immunodeﬁciency virus type 1 (HIV-1) enve-
lope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis
2001;32:801–7.
19] McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P,
et al. Human immunodeﬁciency virus type 1 (HIV-1) gp120-speciﬁc antibod-
ies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis
2001;184:1331–5.
20] Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS,
et al. Safety and immunogenicity of an HIV-1 recombinant canarypox
vaccine in newborns and infants of HIV-1-infected women. J Infect Dis
2005;192:2129–33.
21] McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J,
et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected
mothers. AIDS 2006;20:1481–9.
22] Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T,
et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed
infants in Uganda: results from the ﬁrst HIV vaccine trial in infants in Africa. J
Acquir Immune Deﬁc Syndr 2013;63:1–8.
23] Afolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi S-R, Rowland-Jones SL,
et al. A phase I randomized clinical trial of candidate human immunodeﬁciency
virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One
2013;8:e78289.
24] van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development
andvalidationof amultiplex immunoassay for the simultaneousdetermination
of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol
Methods 2008;335:79–89.
25] Eggers M, Terletskaia-Ladwig E, Rabenau HF, Doerr HW, Diedrich S, Enders
G, et al. Immunity status of adults and children against poliomyelitis virus
type 1 strains CHAT and Sabin (LSc-2ab) in Germany. BMC Infect Dis 2010;
10:347.
26] Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, et al.
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadmin-
istration with EPI vaccines in a randomized controlled trial in Gambian infants.
Sci Transl Med 2011;3:88ra56.
27] Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, et al.
Dose-ﬁnding study of the novel tuberculosis vaccine,MVA85A, in healthy BCG-
vaccinated infants. J Infect Dis 2011;203:1832–43.
28] Hanke T. Conserved immunogens in prime-bost strategies for te next-
generation HIV-1 vaccines. Expert Opin Biol Ther 2014;14:601–16.
29] Hopkins R, Bridgeman A, Bourne C, Mbewe-Mwula A, Sadoff JC, Both GW,
et al. Optimizing HIV-1-speciﬁc CD8+ T-cell induction by recombinant BCG
in prime-boost regimens with heterologous viral vectors. Eur J Immunol
2011;41:3542–52.
30] Hopkins R, Bridgeman A, Joseph J, Gilbert SC, McShane H, Hanke T. Dual
neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 2011;6:
e20067.
31] Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, et al. Vaccine
platform for prevention of tuberculosis and mother-to-child transmission
of human immunodeﬁciency virus type 1 through breastfeeding. J Virol
2007;81:9408–18.
32] Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, Borthwick N, et al. Safety and
immunogenicity of novel recombinant BCG andmodiﬁed vaccinia virus Ankara
vaccines in neonate rhesus macaques. J Virol 2010;84:7815–21.
33] Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, Joseph J, et al.
Novel recombinantMycobacteriumbovisBCG,ovineatadenovirus, andmodiﬁed
vaccinia virus Ankara vaccines combine to induce robust human immunodeﬁ-
ciency virus-speciﬁc CD4 and CD8 T-cell responses in rhesus macaques. J Virol
2010;84:5898–908.
34] Saubi N, Gea-Mallorqui E, Ferrer P, Hurtado C, Sanchez-Ubeda S, Eto Y, et al.
Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine
vectored by lysine auxotroph of BCG. Mol Ther Methods Clin Dev 2014;
1:14017.
35] Saubi N, Im EJ, Fernandez-Lloris R, Gil O, Cardona PJ, Gatell JM, et al. Newborn
mice vaccinationwithBCG.HIVA+MVA.HIVAenhancesHIV-1-speciﬁc immune
responses: inﬂuence of age and immunization routes. Clin Dev Immunol
2011;2011:516219.
36] BorthwickN, AhmedT,OndondoB,Hayes P, RoseA, EbrahimsaU, et al. Vaccine-
elicited humanT cells recognizing conserved protein regions inhibit HIV-1.Mol
Ther 2014;22:464–75.
37] Ewer KJ, O‘Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al.
Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee
adenovirus-MVA immunisation. Nat Commun 2013;4:2836.
38] Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al.
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and
AMA1: assessment of efﬁcacy against mosquito bite challenge in humans. Mol
Ther 2013;20:2355–68.
5 ccine
[
[
[
[
[
[
[
[
[
[
et al. Impaired humoral response to vaccines among HIV-exposed uninfected808 I.N. Njuguna et al. / Va
39] Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design
andpre-clinical evaluation of a universal HIV-1 vaccine. PLoSOne2007;2:e984.
40] McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new pri-
orities and directions. Nat Immunol 2012;13:423–7.
41] McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al.
Recombinant modiﬁed vaccinia virus Ankara expressing antigen 85A boosts
BCG-primed and naturally acquired antimycobacterial immunity in humans.
Nat Med 2004;10:1240–4.
42] Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al.
Safety andefﬁcacyofMVA85A, anewtuberculosis vaccine, in infantspreviously
vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet
2013;381:1021–8.
43] ClericiM, SaresellaM,ColomboF, Fossati S, SalaN, Bricalli D, et al. T-lymphocyte
maturation abnormalities in uninfected newborns and children with vertical
exposure to HIV. Blood 2000;96:3866–71.
44] Kidzeru EB, Hesseling AC, Passmore JA, Myer L, Gamieldien H, Tchakoute
CT, et al. In-utero exposure to maternal HIV infection alters T-cell immune
responses to vaccination in HIV-uninfected infants. AIDS 2014.
[32 (2014) 5801–5808
45] Miyamoto M, Pessoa SD, Ono E, Machado DM, Salomao R, Succi RC, et al. Low
CD4+ T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected
children and adolescents. J Trop Pediatr 2010;56:427–32.
46] Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves AM, et al.
Impaired progenitor cell function in HIV-negative infants of HIV-positive
mothers results in decreased thymic output and low CD4 counts. Blood
2001;98:398–404.
47] Jones SA, Groome M, Koen A, Van Niekerk N, Sewraj P, Kuwanda L, et al.
Immunogenicity of seven-valent pneumococcal conjugate vaccine adminis-
tered at 6, 14 and 40 weeks of age in South African infants. PLoS One
2013;8:e72794.
48] Abramczuk BM, Mazzola TN, Moreno YM, Zorzeto TQ, Quintilio W, Wolf PS,infants. Clin Vaccine Immunol 2011;18:1406–9.
49] Thaithumyanon P, Punnahitananda S, Praisuwanna P, Thisyakorn U,
RuxrungthamK. Antibody response to hepatitis B immunization in infants born
to HIV-infected mothers. J Med Assoc Thai 2002;85:277–82.
